

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Entrectinib for treating NTRK fusion-positive solid
tumours**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

During the scoping process a consultee noted that, if subgroups were considered according to tumour site of origin, eligible patients with rarer tumour types may be disadvantaged by the lower number of existing targeted therapies available and associated diagnostic tests when compared to more common cancers.

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|----|--|

The potential equality issue identified was considered a function of the clinical condition and not the technology under assessment and therefore is not considered an equalities issue.
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No additional stakeholders identified.

Approved by Associate Director (name):

Date: [xx/xx/year]